If you are weighing a pharmacogenomics test in 2026, the rst question is almost always the same: will Medicare or my commercial plan pay for it? The honest answer is that coverage is conditional, not automatic, and the rules have continued to tighten around documentation, gene-drug evidence, and panel size (CMS MolDX LCD L38394, CMS billing article A57384, revised March 5, 2026). Understanding those rules before you test is the di erence between a clean reimbursement and a surprise bill, and it is also how you decide whether a pharmacist-interpreted out-of-pocket package is the better path for your medication history (MedGenyx pricing).

What pharmacogenomics testing actually does:

Pharmacogenomics testing uses a DNA sample, typically collected by cheek swab, to analyze inherited variation in genes that a ect how your body activates, metabolizes, and clears medications (FDA Table of Pharmacogenetic Associations). The result by itself is a lab report. It becomes a clinical tool when a trained pharmacist pairs it with your full medication list, diagnoses, prior drug failures, and side-e ect history, and then translates the ndings into prescribing recommendations your provider can act on (MedGenyx Physicians & Providers, CPIC Guidelines). That distinction — pharmacist-interpreted PGx versus a raw lab printout — is the single most important factor in whether testing actually changes a treatment plan.

When Medicare covers PGx testing in 2026

Medicare can cover PGx testing under the Molecular Diagnostic Services Program (MolDX) when the test is ordered by a treating clinician, is medically necessary, and meets the criteria spelled out in LCD L38394 and the most recent billing article, which was updated again on March 5, 2026 to consolidate the JE and JF contractor jurisdictions (CMS MolDX LCD L38394, CMS billing article A57384). In practice, coverage is most defensible when the medical record documents four things: an active diagnosis, a specic medication-management question, a recognized drug-gene interaction listed in CPIC or FDA labeling, and a clear statement of how the result will change prescribing (CMS billing article A57384, FDA Table of Pharmacogenetic Associations).

Medicare also continues to support drug-speci c PGx testing under National Coverage Determinations, including the longstanding NCD 90.1 framework for CYP2C9 and VKORC1 in warfarin dosing, which shows that even when broad panels face scrutiny, well-supported single-gene tests can still be reimbursed (CMS NCD 90.1, CMS billing article A57384). The MolDX article was further revised on February 5, 2026 to add donanemab alongside lecanemab under APOE testing, re ecting how quickly the covered gene-drug table is expanding as new FDA-labeled therapies appear (CMS billing article A57384, R19).

What Medicare does not cover

Medicare does not cover PGx testing as a wellness screen, a curiosity pro le, or a future-use library when there is no active drug-management question on the table (CMS MolDX LCD L38394). Because inherited variants do not change over time, Medicare also generally does not pay for repeat germline PGx testing that duplicates a prior result, except in narrow circumstances de ned in the Repeat Germline Testing policy (CMS billing article A57384). Only one PGx test is payable per date of service, and that test must be the one most likely to identify the alleles relevant to the drugs in question — a rule that applies to single-gene tests and multigene panels alike (CMS billing article A57384).

It is also worth knowing that 2026 brought a new layer of administrative review to original Medicare. A six-year Wasteful and Inappropriate Services Reduction (WISeR) pilot launched January 1, 2026 in Arizona, New Jersey, Ohio, Oklahoma, Texas, and Washington, adding prior authorization to certain Part B services agged as potentially wasteful (GoodRx Medicare 2026 changes, AARP 2026 Medicare changes). If you live in one of those states, expect more documentation requests on borderline molecular tests, and ask your ordering clinician to con rm prior-authorization status before the sample is collected. 

Commercial coverage in 2026: more variable than Medicare 

Commercial coverage continues to be the more di cult terrain. Most large commercial bene t managers still treat broad multigene PGx panels as not medically necessary unless the test is tied to a speci c FDA-labeled or NCCN-recommended gene-drug pair (Carelon Pharmacogenetic Testing guideline, updated January 1, 2026). Carelon' s 2026 guideline, for example, lists a de ned set of medically necessary gene-drug pairs — including DPYD for capecitabine and uorouracil, CYP2C19 for clopidogrel, HLA-B*5701 for abacavir, HLA-B*1502 for carbamazepine, TPMT and NUDT15 for thiopurines, and APOE for lecanemab and donanemab — while explicitly designating broad psychiatry and multi-gene drug-metabolism panels as not medically necessary (Carelon guideline).

State mandates are moving in the opposite direction in some markets. Maryland' s SB 961, advanced through the Maryland Health Care Commission' s November 2025 review, would require commercial insurers and Maryland Medicaid to cover PGx testing for anxiety and depression — categories that most insurers currently exclude under existing biomarker laws (Maryland Health Care Commission SB 961 analysis). Until those mandates take e ect plan by plan, the practical rule for commercial coverage in 2026 is straightforward: call your insurer before testing, ask whether the speci c CPT codes and genes on your panel are covered, and request written prior-authorization guidance (Carelon guideline).

When insurance says no: what you are actually paying for 

If insurance does not cover your test, transparent package pricing matters more than the headline number, because the di erence between a $200 lab-only kit and a $500 pharmacist- interpreted package is what someone does with the result (MedGenyx pricing). MedGenyx publishes its packages in a single price list ranging from $389 to $899, with each tier specifying the level of pharmacist consultation, comprehensive medication review, provider collaboration, documentation, and ongoing access included (MedGenyx pricing). That service layer is the point: a PGx result becomes useful when it is interpreted alongside your medication list, clinical history, and prescriber' s treatment plan, not when it is led away as a PDF (MedGenyx Physicians & Providers, CPIC Guidelines).

Six questions to ask before you test

Before you commit to any PGx package — covered or self-pay — ask:

 . Can my clinician document medical necessity, including a speci c drug, diagnosis, and prescribing decision the result will inform?

 . Which genes and medications are included on the panel, and do they match the drugs I actually take or am being considered for?

 . Is the laboratory CLIA-certi ed and CAP-accredited?

 . Who interprets the result — a pharmacist with PGx training, an automated software report, or the ordering clinician alone?

 . How does the interpreted result reach my provider, and is the recommendation written in a form they can act on?

 . What follow-up support is included if my medication list changes, or if I start a new drug that interacts with my genotype?

Those questions separate a one-time lab report from a medication-management service, and they are the simplest way to understand exactly what you are buying (MedGenyx FAQ, MedGenyx services, MedGenyx pricing).

The bottom line for 2026

Medicare covers PGx testing in speci c medically necessary situations de ned by MolDX LCD L38394 and the March 5, 2026 billing article, with a continually growing list of covered gene- drug pairs (CMS MolDX LCD L38394, CMS billing article A57384). Commercial coverage in 2026 remains narrower and panel-restrictive, with most insurers following Carelon-style criteria that approve targeted gene-drug pairs and decline broad multi-gene drug-metabolism panels (Carelon guideline). If you are not sure whether PGx testing ts your situation, a discovery call with a consultant pharmacist can clarify what the test can and cannot answer for your medication list before you commit to a package (MedGenyx services).